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Abstract. The changing pattern of prevalence and age
distribution of analgesic nephropathy as a cause of
end-stage renal failure (ESRF) in patients on RRT
was analysed using the EDTA-ERA Registry's files.
Comparing 1990 to 1981, the percentage of patients
with analgesic nephropathy decreased in many
European countries and the Registry's average came
down from 3 to 2%. The highest prevalence was noted
for Switzerland, which showed a decrease from 28 in
1981 to 12% in 1990. During the same interval the age
distribution shifted to the right with an increase in
median age from 57 to 63 at start of RRT for analgesic
nephropathy. In Switzerland the age-specific accept-
ance rate to RRT for patients with analgesic nephro-
pathy decreased to less than 1/3 in the age cohorts
below 55 but increased in those aged 65 or older. This
increase in the elderly cohorts appeared to be related
to the growing acceptance rate to RRT of elderly
patients in general rather than to an increasing incid-
ence of ESRF due to analgesic nephropathy. Mortality
in general and death rates due to cardiovascular causes
were found not to differ in RRT patients with analgesic
nephropathy from that of other standard primary renal
diseases (excluding diabetic nephropathy and systemic
diseases). Some 20 years after withdrawal of phenacetin
from the analgesic market, analgesic nephropathy all
but disappeared as a cause of ESRF in Sweden and
Denmark, and the same may be expected to occur in
countries like Switzerland, Belgium, and others in the
not too far distant future.
Key words: EDTA Registry; analgesic nephropathy;
cardiovascular mortality on renal replacement therapy;
epidemiology of end-stage renal failure due to analgesic
nephropathy
Introduction
During the last three decades we have witnessed a
decrease in the sale and abuse of mixed analgesic drugs
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containing phenacetin in many European countries
due to legal restriction, public education, and finally
by the pharmaceutical companies removing phenacetin
from mixed preparations [1-3]. All these measures
should have affected the epidemiology of analgesic
nephropathy, and the EDTA Registry's files afforded
a unique opportunity to study any changes in the
prevalence of ESRF caused by this condition. The
Registry's files were also used to detect possible differ-
ences in overall and cardiovascular mortality on RRT,
comparing analgesic nephropathy to standard primary
renal diseases.
Methods
The methods of data collection used by the EDTA
Registry have been described previously [4]. This
report is based on data provided on individual patient
questionnaires and relates to treatment up to
31 December 1990. The percentage of centres reporting
their patients to the EDTA-ERA Registry varied
between 50% and 100% for the countries mentioned
specifically in this report. The analyses were carried
out by the methodology developed by Dr Neville
Selwood as previously described [5]. Age and sex
specific acceptance rates to RRT were calculated for
Switzerland, where patient questionnaire returns have
been 80% to 90% complete and where the total number
of new patients has been checked every year by tele-
phone calls to non-reporting centres by FB.
Results and comments
Prevalence and age distribution at start of RRT
As judged by the proportion of patients starting RRT
due to analgesic nephropathy and their age distribu-
tion, the prevalence of analgesic nephropathy has been
changing in Europe. Comparing 1990 to 1981, the
proportion with analgesic nephropathy as a percentage
of all patients starting RRT decreased in most
European countries (Figure 1). The highest proportion
was noted for Switzerland, with 28% of patients in
1981 and a lower but still remarkable 12% in 1990.
© 1994 European Dialysis and Transplant Association-European Renal Association
1372 F. P. Brunner and N. H. Selwood
30
% patients with AN at start of RRT
2 5 -
2 0 -
15
10-
5"
0-4
wilt B Den A Neth W-Oerm CS S F I
Fig. 1. Proportion of patients with analgesic nephropathy at start
of RRT shown for the total registry (EDTA), for all countries above
the EDTA average (Switzerland, Belgium, Denmark, Austria,
Netherlands, Germany, Czechoslovakia) and for selected countries
with lower proportions (Sweden is shown because of its high
prevalence of analgesic nephropathy in the 1960s and France and
Italy were selected as the two countries with the largest number of
patients on RRT and of inhabitants).
For Belgium the percentage decreased from 16% to
11%. In most other countries there was also a decrease
to be noted comparing 1990 to 1981. The EDTA
average decreased from 3% in 1981 to 2% in 1990. The
proportion of patients with analgesic nephropathy
accepted for RRT was recorded for every EDTA
country in the 1988 combined report [6]. The percent-
age of patients accepted for RRT in 1987 with analgesic
nephropathy for countries not listed in Figure 1 was
3.2% in Portugal, 2.9% in Cyprus, 2.7% in the German
Democratic Republic, 1% in the United Kingdom, and
less than 1% in all other countries [6].
Analgesic abuse has been more prevalent among
females, and this is shown again as the female:male
ratio for all patients starting RRT between 1970 and
1990 (Figure 2). The EDTA average was 2.7 females
for 1 male, and Belgium had the highest preponderance
of females with a ratio of 4.9.
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The age distribution of all patients with analgesic
nephropathy at start of RRT shifted to the right
comparing 1990 to 1980 as shown in Figure 3. In 1980
some 30% or more were in each of the cohorts aged
45-54 and 55-64. In 1990 there were barely any
patients aged below 35, but over 30% were now in the
age group 65-74 and 10% above age 75. Median age
rose from about 57 in 1980 to 63 in 1990. Similar
changes in age distribution have been reported from
Australia [7].
The changing pattern of analgesic nephropathy can
be appreciated best in Switzerland where this disease
was first described in 1953 [8] and where it has had
the highest prevalence worldwide over the last decades.
The age-specific acceptance rate for Swiss patients with
analgesic nephropathy is shown for 1980 and 1990 in
Figure 4a (identical trends were observed regarding
the age-specific acceptance rates in both sexes). In 1980
some 40 patients per million population aged 45-54
and about 60 patients p.m.p. aged 55-64 (or more
than 100 per million females aged 55-64 and over 30
per million males aged 55-64) were accepted for RRT
with ESRF attributed to analgesic nephropathy. Ten
years later, in 1990, not a single patient starting RRT
for analgesic nephropathy was below age 35, and very
few were in the cohorts 35-44 and 45-54. A definite
decrease is also demonstrated for the cohort aged
55-64. However, the number of patients aged 65-74
more than doubled and there were some 10 per million
population aged above 75 who started dialysis for
ESRF due to analgesic nephropathy in 1990. Almost
identical numbers and trends in the age-specific accept-
ance rates have been recorded in Australia between
1981 and 1991 [7].
One explanation for this increasing incidence in
elderly patients could be the well-known fact that
many patients discontinued analgesic abuse with phen-
acetin-containing mixed analgesics once renal disease
had been detected or when phenacetin was more diffi-
cult to obtain. This could have lessened further damage
to the kidneys and delayed the appearance of ESRF
from age 40-50 to age 70 or 80. Another explanation
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Fig. 2. Female:male ratio of patients starting RRT for end-stage
renal failure due to analgesic nephropathy in 1970-1990, shown for Fig. 3. Age distribution of patients starting RRT for end-stage renal
selected countries. failure due to analgesic nephropathy in 1980 and in 1990.
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Fig. 4. End-stage renal failure due to analgesic nephropathy in Switzerland, a. Age-specific acceptance rate (per million general population
of same age cohort); b. patients with analgesic nephropathy as a percentage of all patients accepted for for RRT.
is suggested by Figure 4b, which shows the percentage
of patients with analgesic nephropathy as a proportion
of all patients starting RRT in each age cohort separ-
ately for 1979/80 and for 1989/90. It is important to
note that the percentage in the age group 65-74 and
above 75 did not change over this 10-year interval.
There is no doubt, therefore, that the number of
patients with end-stage renal failure due to analgesic
nephropathy has been decreasing during the 1980s in
Switzerland at least up to the age of 65. In patients
above the age of 65, the true incidence of end-stage
renal failure due to analgesic nephropathy has prob-
ably remained stable, and the increased acceptance
rate was the result of an increased acceptance rate of
elderly patients in general.
Mortality and death rates due to cardiovascular causes
Accelerated artherosclerosis with coronary, carotid,
renal, and peripheral arterial occlusive disease has been
reported to cause serious morbidity and premature
mortality in patients with analgesic nephropathy,
mainly from Australia [9] but also from Switzerland
[10]. The study from Australia [9] compared patients
with analgesic nephropathy to patients with glomerulo-
nephritis accepted for RRT during the same 5-year
period. Overall mortality was significantly higher in
the former group with 50.8 versus 15.8%. However,
no details regarding age distribution and other pro-
gnostic features of the two patient groups were given.
In the 20-year longitudinal study of initially healthy
female factory workers without renal disease from
Switzerland [10] a group with analgesic abuse was
compared to a matched control group without abuse.
The risk of renal or cardiovascular disease was
increased in the group with analgesic abuse but end-
stage renal disease was a rare event. It seemed import-
ant therefore to analyse overall mortality and death
rates due to cardiovascular causes in typically
European patient cohorts on RRT with analgesic
nephropathy in comparison to all patients with stand-
ard primary renal diseases (glomerulonephritis,
pyelonephritis/interstitial nephritis, polycystic kidney
diseases) as shown in Figures 5-8. These analyses were
restricted to Belgium, The Netherlands, Germany,
Switzerland, and Austria, i.e. countries with a sizeable
proportion of patients with analgesic nephropathy. In
contrast to the findings reported from Australia [9]
mortality did not differ appreciably between the
cohorts with analgesic nephropathy as compared to
those with other standard primary renal diseases.
Furthermore mortality in females with analgesic
nephropathy was slightly lower compared to males, as
has been reported for European patients with other
common renal diseases [11].
Cardiovascular mortality including death rates due
to myocardial ischaemia and infarction have long been
known to be increased in patients on RRT as recorded
again in recent EDTA reports [11,12]. Of particular
interest were the geographical differences in the coron-
ary death rates on RRT, which reflected the pattern in
the general population of higher death rates due to
myocardial ischaemia and infarction in Northern
versus Southern Europe. These geographical differ-
ences made it important to restrict the analyses of
cardiovascular death rates in patients with analgesic
nephropathy to countries in central Europe with similar
risks of cardiovascular death in the general population.
Death rates due to myocardial ischaemia and infarction
(Figure 6) were slightly higher in male patients than
in female patients but did not differ appreciably
between patients with analgesic nephropathy as com-
pared to patients with other primary renal diseases.
The same was true for other cardiac causes (Figure 7).
Lethal cerebrovascular accidents (Figure 8) had not
only a similar incidence in males compared to females
but also occurred at similar rates in patients with
analgesic nephropathy.
Hence we may conclude that patients on RRT due
to analgesic nephropathy have an overall mortality
and cardiovascular death rates related to end-stage
renal failure in general, as observed in other patient
groups with standard primary renal diseases.
Conclusions regarding the incidence of analgesic
nephropathy as a cause of end-stage renal failure
The sale of phenacetin-containing mixed analgesics
was discontinued in the early 1960s in Sweden [1]. The
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Fig. 5. Average yearly mortality during the first 5 years of RRT in patients starting treatment in 1980-1985 in Austria, Belgium, FRG,
Netherlands, and Switzerland. Mortality per thousand patient years at risk is shown separately for patients with analgesic nephropathy
(AN) and for patients with all other standard primary renal diseases.
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Fig. 6. Average annual death rates per 1000 patient years due to myocardial ischaemia and infarction (same patient groups, countries, and
periods of time as Figure 5).
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Fig. 7. Average annual death rates per 1000 patient years due to cardiac causes excluding myocardial ischaemia and infarction (same
patient groups, countries, and periods of time as Figure 5).
proportion of patients with analgesic nephropathy as decreased further to 2% in 1980 (Figure 9). Analgesic
a cause of end-stage renal failure in Sweden had nephropathy has now almost disappeared in Sweden
probably decreased slightly by 1970, with 10% of all and there was only a small number of old patients
patients accepted for RRT at that time, and this starting RRT for analgesic nephropathy in 1990 in
EDTA Registry report on analgesic nephropathy
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Fig. 8. Average annual death rates per 1000 patient years due to cerebrovascular accident (same patient groups, countries, and periods of
time as Figure 5).
% patients with AN at start of RRT
JO -
30 -
2 5 -
2 0 -
1 5 -
1 0 -
5 -
o-
(MS! Sweden ^M Denmark fSSM Switzerland
26
17
i IHIII in
9 I! 1 ll
II J
•Wii MWMl—1980 1990
Fig. 9. Proportion of patients with analgesic nephropathy at start
of RRT in Sweden, Denmark, and Switzerland in 1970, 1980,
and 1990.
Sweden. In Denmark, the restriction to the sales of
phenacetin-containing mixed analgesics came into
effect during the early 1960s but phenacetin continued
to be available on prescription only until 1984. The
percentage of Danish patients with analgesic nephro-
pathy at start of RRT decreased from 14% in 1970 to
9% in 1980 and was as low as 3% in 1990. In
Switzerland the highest proportion was recorded in
1980 and 1981 with some 26-28% of patients starting
RRT during those years. Phenacetin has been disap-
pearing rather slowly from the market in Switzerland
and was still available in a few mixed analgesics in the
late 1980s. We may expect that some 10-20 years hence
analgesic nephropathy will no longer be a significant
cause of end-stage renal failure in Switzerland and
other countries as was the case in Sweden some 20
years after the disappearance of phenacetin.
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